Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P950037/S298

Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos

Biotronik, Inc. · Decision date Oct 13, 2026

MEDTECHLEDGER EXPLANATIONP950037/S298

What did the FDA decide?

FDA recorded a 30-Day Notice decision (OK30) dated 2026-10-13 for PMA supplement P950037/S298 from Biotronik, Inc. The supplement covers a change to the rework process for manufacturing the housing of pulse generators and ICDs. The listed products are the Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR and Enticos, under product code DXY in the cardiovascular specialty.

The supplement reason is recorded as a process change affecting manufacturer, sterilizer, packager or supplier. This entry documents a manufacturing-process modification within the existing P950037 PMA; it is not a new approval of the device system. The source provides no detail on the specific housing rework steps, validation data or affected manufacturing sites, and no FDA documents are attached, so the technical scope of the change remains unknown.

Whether the rework change alters device performance or requires additional review beyond this notice cannot be determined from the available fields. Any clinical or regulatory interpretation of the change's effect would exceed the recorded data.

FDA approval order statement

a change to the rework process for the manufacturing of the housing for pulse generators and ICDS
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 13, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P950037/S298
Regulatory pathway
PMA supplement
Product code
DXY
Decision code
OK30
Decision date
Oct 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: implantable pacemaker Pulse-generator.

Product code
DXY
FDA device class
3

For the original device and its historical approval scope, see PMA P950037. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P950037 · Original PMA

    DROMOS DR/DR-A AND DROMOS SR/SR-B CARDIAC PACING SYSTEMS

  2. P950037/S291 · Related supplement

    PSW 2601.U, NEO 2601.U, Amvia Sky HF-T QP, Amvia Sky HF-T, Amvia Edge HF-T QP, Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edg

  3. P950037/S298 received

    Application receipt date recorded by FDA.

  4. P950037/S279 · Related supplement

    Edora 8 DR-T 407145, Evity 8 DR-T 407146, Enitra 8 DR-T 407147, Enticos 8 DR-T 407148, Evity 6 DR-T 407149, Enitra 6 DR-

  5. P950037/S296 · Related supplement

    Edora 8 DR-T 407145; Evity 8 DR-T 407146; Enitra 8 DR-T 407147; Enticos 8 DR-T 407148; Evity 6 DR-T 407149; Enitra 6 DR-

  6. P950037/S298 · FDA decision

    30-Day Notice

  7. P950037/S299 · Related supplement

    Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8

  8. P950037/S300 · Related supplement

    Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,

Timeline entries are records held by MedtechLedger for P950037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P950037

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records